RenovoRx (RNXT) Cash from Operations (2020 - 2026)

RenovoRx has disclosed Cash from Operations across 7 years of filings, most recently posting -$2.9 million for Q2 2026.

• In Q2 2026, Cash from Operations fell 24.54% year-over-year to -$2.9 million; the TTM figure through Jun 2026 stood at -$11.9 million (down 15.13% YoY), while the FY2025 annual figure was -$11.0 million, down 20.25% from the prior year.
• Cash from Operations came in at -$2.9 million for Q2 2026 at RenovoRx, up from -$3.7 million in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of -$1.7 million in Q4 2022 to a low of -$3.7 million in Q1 2026.
• Average Cash from Operations over 5 years is -$2.5 million, with a median of -$2.4 million recorded in 2022.
• The largest YoY upside for Cash from Operations was 34.28% in 2022 against a maximum downside of 138.78% in 2022.
• Over 5 years, Cash from Operations stood at -$1.7 million in 2022, then declined by 22.13% to -$2.1 million in 2023, then decreased by 18.36% to -$2.4 million in 2024, then decreased by 24.28% to -$3.0 million in 2025, then climbed by 5.07% to -$2.9 million in 2026.
• Per Business Quant data, the three most recent Cash from Operations figures were -$2.9 million in Q2 2026, -$3.7 million in Q1 2026, and -$3.0 million in Q4 2025.